AroCell and Corgenix establish the measurement of Thymidine Kinase.

| April 15, 2019

article image
This collaboration will make AroCell’s patented biomarker assay available both as a service and as in the already existing AroCell TK 210 ELISA kit for measurements of TK1 protein concentrations in human serum samples. This will provide maximum flexibility for our customers in the USA. It also extends the services that Corgenix offers in their CAP compliant CLIA-lab (Clinical Laboratory Improvement Amendments-lab). Corgenix has over 25 years of experience in the In Vitro Diagnostic (IVD) industry focused on product development, manufacturing, regulation, distribution and contract services with a CAP/CLIA-lab based in Colorado, USA. A CAP/CLIA-lab is a clinical laboratory for human sample testing that follow CAP standards in USA. 

Spotlight

PerformRx

Formed in 1999, PerformRx, LLC is a URAC accredited pharmacy benefits manager servicing lines of business including Medicaid, Medicare, and Commercial markets. A large percentage of the staff at PerformRx are pharmacists and pharmacy technicians. This ensures that the company maintains a culture of clinical influence and care throughout each business area. Clients receive a personalized solution designed to understand their benefit and meet their needs. This includes offering clients standalone products and services as well as full pharmacy benefit management. PerformRx ensures these solutions by utilizing technology that adapts to specific member populations and changes in the health care landscape.

OTHER ARTICLES

Top Specialty Pharmacy Therapy Areas

Article | March 16, 2020

Accelerated by advancements in cancer treatments and a growing emphasis on personalized and precision medicine, specialty pharmacy represents a rapidly growing sector within the healthcare industry. In fact, the market is projected to grow to $500 billion by the end of this year—up from $200 billion in total U.S. specialty drug spending in 2017. Industry growth of this magnitude creates challenges for those looking to understand and penetrate the market. It can be difficult, after all, to maintain updated information about high-priority drug therapy areas or facility affiliations in a market that’s constantly changing.

Read More

How AI and Big Data Will Disrupt Pharma’s Regulatory Compliance Standards

Article | March 16, 2020

The industry as we know it is changing. Pharmaceutical and life sciences companies across the globe are experiencing more pressure than ever to keep up with increased regulatory standards while moving at a pace that requires them to innovate in order to remain competitive. With more real-time automation and the steady increase in AI and Big Data sweeping the landscape, what used to be a slow-to-change and risk-averse industry is now expected to see a significant shift towards newer technology that focus on heightened regulatory standards. Here’s how your company can get ahead of what industry experts are calling, Pharma

Read More

Roche Prepares to Launch COVID-19 Antibody Test System

Article | March 16, 2020

Swiss pharma giant Roche is joining the race to develop a test for COVID-19 antibodies in people who have been exposed to the disease. This morning, Roche announced the development and upcoming launch of its Elecsys Anti-SARS-CoV-2 serology test to detect antibodies in people who have been exposed to the SARS-CoV-2, the virus that causes COVID-19. Roche is eying May for the launch of the test in Europe and is in talks with the U.S Food and Drug Administration for emergency approval of the system. Antibody testing is central to help identify people who have been infected by the virus, especially those who may have been infected but did not display symptoms, the company said. Roche noted that as more information becomes available about immunity levels to COVID-19, society can return to a sense of normal much more quickly. Roche’s test will join a number of other antibody tests that have recently come on the market. Earlier this month the U.S. Food and Drug Administration approved the first blood test for COVID-19 antibodies.

Read More

Clinical Development Risks and Issues in a COVID-19 World

Article | March 16, 2020

Global clinical guidelines have shifted the industry toward risk-based approaches for the planning and execution of clinical trials. The ICH’s guidelines for Good Clinical Practice state that sponsors should evaluate identified risks against existing risk controls by considering “the likelihood of errors occurring, the extent to which such errors would be detectable, and the impact of such errors on human subject protection and reliability of trial results” (ICH E6 R2).

Read More

Spotlight

PerformRx

Formed in 1999, PerformRx, LLC is a URAC accredited pharmacy benefits manager servicing lines of business including Medicaid, Medicare, and Commercial markets. A large percentage of the staff at PerformRx are pharmacists and pharmacy technicians. This ensures that the company maintains a culture of clinical influence and care throughout each business area. Clients receive a personalized solution designed to understand their benefit and meet their needs. This includes offering clients standalone products and services as well as full pharmacy benefit management. PerformRx ensures these solutions by utilizing technology that adapts to specific member populations and changes in the health care landscape.

Events